Dewm, we've agreed on many things but the CEO removal idea is not one of them. We are all arm-chair quarterbacks at times but when BIELs products end up in CVS and Walgreens in 2018, will you be saying the same thing about the CEO? I was reminded (amidst the flurry of frustration) by srinsocal of these truths and so I cannot agree about the CEO being removed. Quite the contrary---below represents momentum:
* BIEL has signed with a Distributor that services 10,000 Independent Pharmacies, products on shelves before EOY
* All of the data has been received for the 100 patient Back Study, when data is analyzed Study will be submitted to FDA for Full Body Musculoskeletal Clearance
* Recruitment started for Allay Study by Birmingham Woman's Hospital UK
* "Pain Gear", ActiPatch licensed to PharmEvo, is selling well in Asia, PharmEvo, with 800 Sales Reps and it's own Clinical Trial business, has initiated a 200 person Clinical Trial and held a conference to educate 150 doctors on the Pain Gear product
* BIEL in talks with Chain Store that handles 25% of US prescriptions
* BIEL has hired Keith Nalepka as VP of Sales, Keith has placed over $500 Million in health related products on US retail shelves
* ActiPatch Migraine Study is near completion, results to be released at any time
* 10,200 unit ActiPatch order sold to Distributor in Spain
* BIEL exhibited ActiPatch at MEDICA, the largest Medical Convention in the World last week, New distributors have been added at every previous MEDICA Conference that BIEL has attended, first one since FDA OTC Clearance
* POTUS Declares Opioid Crisis a National Health Emergency, Thousands Die from Opioid Abuse each month, the need for Drug Free Pain Relief is urgently needed
* November 2017, BIEL is offering Free 7 Day Trial ActiPath units to US consumers
